One type of stem cell transplant,
autologous hematopoietic stem cell transplantation, uses stems cells from your own bone marrow, or from external umbilical cord blood.
The Treatment:
Autologous hematopoietic stem cell transplantation (AHSCT) is an aggressive procedure which involves collecting stem cells from an...
In addition, transgenic
autologous hematopoietic stem cells can be successfully transplanted in HIV - infected individuals [18] and several phase I adoptive transfer trials of CD4 + T cells treated with R5 - ZFNs in HIV infected individuals are currently underway.
Along with the investigational monoclonal antibody, study participants underwent multi-drug chemotherapy, surgery, radiation and
autologous hematopoietic stem cell transplantation.
Although many immunosuppressive strategies have failed, the recent use of
autologous hematopoietic stem and progenitor cell (HSPC) transplantation has shown therapeutic promise.
The treatment in the current study, called
autologous hematopoietic stem cell transplantation (AHSCT), was given to patients with advanced forms of the disease that had failed to respond to other medications.
Autologous hematopoietic stem cell transplantation (AHSCT) has been investigated as a treatment for aggressive MS, the rationale for which is immune reconstitution.
While some previous studies found that maintenance lenalidomide after
autologous hematopoietic stem cell transplant improved overall survival for newly diagnosed multiple myeloma patients, others showed no benefit to this approach.
Not exact matches
«The ability to control autoimmunity by
autologous HSCT [
hematopoietic stem cell transplantation] has been demonstrated in other treatment - refractory autoimmune conditions, including neurologic diseases.
Journal reference: JAMA, C - Peptide Levels and Insulin Independence Following
Autologous Nonmyeloablative
Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus
However, coreceptor - specific ZFNs represent a novel therapeutic approach to recapitulate this success via
autologous transplantation of gene - modified
hematopoietic stem cells and mature CD4 + T cells.
Plerixafor has been approved by the FDA as the first small - molecule CXCR4 antagonist for use in combination with granulocyte - colony stimulating factor (GCSF) to mobilize
hematopoietic stem cells to the bloodstream for collection and subsequent
autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
Hematopoietic stem cells express the markers CD34 and CD133 and can repopulate a myeloablated recipient after allogeneic or
autologous transplantation.
For example, we have no information about how these newly - generated HPCs will compete with
autologous bone marrow cells for
hematopoietic niches in the recipient mice.